

DAFTAR PUSTAKA

1. Kocarnik J. Cancer's global epidemiological transition and growth. Lancet. 2020;395(10226):757–8.
2. Stefan N, Häring HU, Hu FB, Schulze MB. Divergent associations of height with cardiometabolic disease and cancer: Epidemiology, pathophysiology, and global implications. Lancet Diabetes Endocrinol. 2016;4(5):457–67.
3. World Health Organization. Cancer Country Profiles. 2014. http://www.who.int/cancer/countryprofiles/idn_en.pdf?ua=1 – Diakses Maret 2020
4. Kementerian Kesehatan RI. Penyakit Kanker di Indonesia Berada pada Urutan 8 di Asia Tenggara dan Urutan 23 di Asia. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. 2018. <http://p2p.kemkes.go.id/penyakit-kanker-di-indonesia-berada-pada-urutan-8-di-asia-tenggara-dan-urutan-23-di-asia/> - Diakses Juni 2020
5. Zappa C, Mousa SA. Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300.
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.
7. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science (80-). 2004;304(5676):1497–500.
8. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101(36):13306–11.
9. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339–46.
10. Syahruddin E, Wulandari L, Muktiati NS, Rima A, Soeroso N, Ermayanti S, et al. Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients. Lung Cancer Targets Ther. 2018;9:25–34.
11. Tarigan ASB. Korelasi Gambaran CT Scan dengan Mutasi EGFR Pada Pasien Adenokarsinoma Paru (studi Retrospektif di RSUD Soetomo Januari 2015 - Desember 2017). Universitas Airlangga. Universitas Airlangga; 2018.
12. Liu Y, Kim J, Qu F, Liu S, Wang H, Balagurunathan Y, et al. CT features

- associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. *Radiology*. 2016;280(1):271–80.
13. Cheng Z, Shan F, Yang Y, Shi Y, Zhang Z. CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: A systematic review and meta-analysis. *BMC Med Imaging*. 2017;17(1):1–10.
 14. Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, et al. Longitudinal analysis of 2293 NSCLC patients: A comprehensive study from the TYROL registry. *Lung Cancer* [Internet]. 2015;87(2):193–200.
 15. Zheng M. Classification and Pathology of Lung Cancer. *Surg Oncol Clin N Am*. 2016;25(3):447–68.
 16. Kacmarek RM, Stoller JK, Heuer AJ. Egan's fundamental of respiratory care. 11th ed. Chatburn RL, Kallet RH, editors. Boston, Massachusetts: Elsevier Ltd; 2017.
 17. Tartar A, Kilic N, Akan A. Classification of pulmonary nodules by using hybrid features. *Comput Math Methods Med*. 2013;2013.
 18. Kementerian Kesehatan. Hari Kanker Sedunia 2019. Kementerian Kesehatan. 2019. <https://www.kemkes.go.id/article/view/19020100003/hari-kanker-sedunia-2019.html> - Diakses September 2020
 19. Kementerian Kesehatan RI Badan Penelitian dan Pengembangan. Hasil Utama Riset Kesehatan Dasar. Kementerian Kesehat Republik Indones. 2018;1–100.
 20. U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Department of Health and Human Services, Public Health Service, Office of Surgeon General; 2010. 792 p.
 21. Blackwell W. Lung Cancer. 4th ed. Roth JA, Hong WK, Komaki RU, editors. New Jersey: John Wiley and Sons Inc; 2014. 2677–2678 p.
 22. Parker MS, Groves RC, Kusmirek JS, Gharai LR, Shojaee S. Lung Cancer Screening. Vol. 3, World. New York: Thieme; 2018. 53–60 p.
 23. Wild CP. World Cancer Report 2014. New York; 2014.
 24. World Health Organization. Indonesia Tobacco Factsheet 2018. Who. 2018;1(1):1–2.
 25. Lantz PM, Mendez D, Philbert MA. Radon, smoking, and lung cancer: The need to refocus radon control policy. *Am J Public Health*. 2013;103(3):443–7.
 26. Haugen A, Mollerup S. Textbook of Lung Cancer. In: Hansen H, editor. London: Informa Healthcare; 2008. p. 1–8.

27. Schwartz AG, Cote ML. Epidemiology of lung cancer. *Adv Exp Med Biol.* 2016;893:21–41.
28. Loomis D, Guha N, Hall AL, Straif K. Identifying occupational carcinogens: An update from the IARC Monographs. *Occup Environ Med.* 2018;75(8):593–603.
29. Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. *Eur Respir J.* 2016;48(3):889–902.
30. Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. *Oncotarget.* 2016;7(48):78985–93.
31. North CM, Christiani DC. Women and Lung Cancer: What is New? *Semin Thorac Cardiovasc Surg.* 2013;25(2):87–94.
32. White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Jane Henley S. Age and cancer risk: A potentially modifiable relationship. *Am J Prev Med.* 2014;46(31):1–16.
33. Rajalakshmi TR, Aravindhababu N, Shanmugam KT, Masthan KMK. DNA adducts-chemical add-ons. *J Pharm Bioallied Sci.* 2015;7(4):S197–9.
34. Davidson MR, Gazdar AF, Clarke BE. The pivotal role of pathology in the management of lung cancer. *J Thorac Dis.* 2013;5(5).
35. Hasral A, Dewi FL, Indriani, Kurnianda J, Pratiwi KBH, Supriana N, et al. Panduan Penatalaksanaan Kanker Paru. Komite Penanggulangan Kanker Nasional. Jakarta: Kementerian Kesehatan Republik Indonesia; 2017.
36. Ost DE, Yeung SCJ, Tanoue LT, Gould MK. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. *Chest.* 2013;143(5):121–41.
37. Price SA, Wilson LM. Patofisiologi Proses-Proses Penyakit. 6th ed. Jakarta: Penerbit Buku Kedokteran EGC; 2006.
38. Jusuf A, Hudoyo A, Andriani R, Imaniar R. Diagnosis Kanker Paru. In: Jusuf A, editor. Dasar-dasar diagnosis kanker paru. Jakarta: UI Press; 2017. p. 127–64.
39. Perhimpunan Dokter Paru Indonesia. Kanker Paru Pedoman Diagnosis & Penatalaksanaan di Indonesia. PDPI. Jakarta; 2003. p. 19
40. Sudoyono AW, Setiyahadi B, Alwi I, Simadibrata M, Setiati S. Buku Ajar Penyakit Dalam. 6th ed. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam; 2009.
41. Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, et al. Evaluation of individuals with pulmonary nodules: When is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines.

- Chest. 2013;143(5):93–120.
42. Sommer G, Tremper J, Koenigkam-Santos M, Delorme S, Becker N, Biederer J, et al. Lung nodule detection in a high-risk population: Comparison of magnetic resonance imaging and low-dose computed tomography. *Eur J Radiol*. 2014;83(3):600–5.
 43. Brenner AI, Koshy J, Morey J, Lin C, Dipoce J. The bone scan. *Semin Nucl Med* [Internet]. 2012;42(1):11–26.
 44. Chichra A, Makaryus M, Chaudhri P, Narasimhan M. Ultrasound for the pulmonary consultant. *Clin Med Insights Circ Respir Pulm Med*. 2016;10:1–9.
 45. Van Der Heijden EHFM, Candoli P, Vasilev I, Messi A, Pérez Pallarés J, Yablonskii P, et al. Image enhancement technology in bronchoscopy: A prospective multicentre study in lung cancer. *BMJ Open Respir Res*. 2018;5(1):1–10.
 46. Chockalingam A, Hong K. Transthoracic needle aspiration: The past, present and future. *J Thorac Dis*. 2015;7:S292–9.
 47. Glehr M, Leithner A, Gruber G, Wretschitsch P, Zacherl M, Kroneis T, et al. A new fine-needle aspiration system. *Surg Innov*. 2010;17(2):136–41.
 48. Tuzi A, Bolzacchini E, Suter MB, Giaquinto A, Passaro A, Gobba S, et al. Biopsy and re-biopsy in lung cancer: The oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration. *J Thorac Dis*. 2017;9(3):S405–9.
 49. Ammanagi AS, Dombale VD, Miskin AT, Dandagi GL, Sangolli SS. Sputum cytology in suspected cases of carcinoma of lung (Sputum cytology a poor man's bronchoscopy!). *Lung India*. 2012;29(1):19–23.
 50. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage Classification. *Chest*. 2017;151(1):193–203.
 51. Akoh JA. *World Journal of Transplantation*. 2011;1(1):4–12.
 52. Reddi H. Mutations in the EGFR Pathway. *Am Assoc Cancer Res*. 2013;1.
 53. Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: A review of available methods and their use for analysis of tumour tissue and cytology samples. *J Clin Pathol*. 2013;66(2):79–89.
 54. Brambilla E, Gazdar A. Pathogenesis of lung cancer signalling pathways: Roadmap for therapies. *Eur Respir J*. 2009;33(6):1485–97.
 55. Aboud NM Al, Basit H, Al-Jindan FA. Genetics, DNA Damage and Repair. *StatPearls*. 2020.
 56. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. Molecular Cell Biology. 4th ed. New York: W.H Freeman; 2000.

57. Yoshida T, Zhang G, Haura EB. Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer. *Biochem Pharmacol*. 2010;80(5):613–23.
58. Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. *J Clin Oncol*. 2013;31(8):1070–80.
59. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. *FEBS J*. 2010;277(2):301–8.
60. He M, Capellett M, Nafa K, Yun C-H, Arcila ME, Miller VA, et al. EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations. *Clin Cancer Res*. 2012;18(6):1790–7.
61. Matsuo K, Ito H, Yatabe Y, Hiraki A, Hirose K, Wakai K, et al. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: Assessment of smoking and sex by a case-control study in Japanese. *Cancer Sci*. 2007;98(1):96–101.
62. Ouyang W, Yu J, Huang Z, Chen G, Liu Y, Liao Z, et al. Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. *J Cancer*. 2020;11(8):2060–7.
63. Denis MG, Lafourcade MP, Le Garff G, Dayen C, Falchero L, Thomas P, et al. Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study. *J Thorac Dis*. 2019;11(4):1370–8.
64. P. Federle M, Rosado-de-Christenson M, P. Raman S, W. Carter B, J. Woodward P, M. Shaaban A. Imaging Anatomy Chest, Abdomen, Pelvis. *Journal of Chemical Information and Modeling*. 2017.
65. Truong MT, Wu CC, Carter BW, Bradley S. Sabloff. Pulmonary Tumors and Lymphoproliferative Disorders. In: Shepard J-AO, editor. *Thoracic Imaging*. 3rd ed. Philadelphia: Elsevier Inc.; 2019. p. 406–27.
66. Wu CC, Klein JS. Lung Cancer : Radiologic, Manifestations, and Diagnosis. In: Walker CM, Chung JH, editors. *Muller's Imaging of The Chest*. 2nd ed. Philadelphia: Elsevier Inc.; 2019. p. 324–40.
67. Rizzo S, Raimondi S, de Jong EEC, van Elmpt W, De Piano F, Petrella F, et al. Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients—An external validation. *Eur J Radiol* [Internet]. 2019;110(June 2018):148–55. Available from: <https://doi.org/10.1016/j.ejrad.2018.11.032>
68. Snoeckx A, Reyntiens P, Desbuquoit D, Spinhoven MJ, Van Schil PE, van Meerbeeck JP, et al. Evaluation of the solitary pulmonary nodule: size matters, but do not ignore the power of morphology. *Insights Imaging*. 2018;9(1):73–86.

69. Guan J, Chen M, Xiao N, Li L, Zhang Y, Li Q, et al. EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan. *Med Oncol*. 2016;33(1):1–8.
70. Zhao J, Dinkel J, Warth A, Penzel R, Reinmuth N, Schnabel P, et al. CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation. *PLoS One*. 2017;12(9):1–14.
71. Mirsadraee S. The 7th lung cancer TNM classification and staging system: Review of the changes and implications. *World J Radiol*. 2012;4(4):1-17.
72. Han J, Xiang H, Ridley WE, Ridley LJ. Pleural tail sign: pleural tags. *J Med Imaging Radiat Oncol*. 2018;62:37.
73. Hasegawa M, Sakai F, Ishikawa R, Kimura F, Ishida H, Kobayashi K. CT features of epidermal growth factor receptor-mutated adenocarcinoma of the lung: Comparison with nonmutated adenocarcinoma. *J Thorac Oncol*. 2016;11(6):819–26.
74. Zou J, Lv T, Zhu S, Lu Z, Shen Q, Xia L, et al. Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma. *Thorac Cancer*. 2017;8(3):260–70.
75. Sugiyo D, Caesaria R. Umur dan Perubahan Kondisi Fisiologis Terhadap Kemandirian Lansia. *Muhammadiyah J Nurs*. 2015;21–7.
76. Ahmad OB, Boschi-pinto C, Lopez AD. Age standardization of rates: a new WHO standard. *GPE Discuss Pap Ser*. 2001;(31):1–14. 77.
77. Centers for Disease Control (CDC). History of Smoking. Amerika Serikat: CDC; 2017.
78. Taufik H, Soeroso NN, Tarigan SP, Mutiara E. Proporsi Mutasi Gen Epidermal Growth Factor Receptor (EGFR) dari Biopsi Jaringan dan Plasma ctDNA Pada Adenokarsinoma Paru. *J Respirologi Indones*. 2020;40(3):150–4.
79. Rahmayani TP. Proporsi Hasil Pemeriksaan Epidermal Growth Factor Receptor (EGFR) pada Pasien Kanker Paru Jenis Adenokarsinoma di RSUP Haji Adam. Universitas Sumatera Utara; 2018.
80. Putriani FA, Kholis FN, Purwoko Y. Perbedaan Faktor Risiko Penderita Adenokarsinoma Paru Dengan Mutasi Egfr Dan Non Mutasi Egfr. *Diponegoro Med J (Jurnal Kedokt Diponegoro)*. 2019;8(1):214–21.
81. Tezel GG, Şener E, Aydin Ç, Önder S. Prevalence of epidermal growth factor receptor mutations in patients with non-small cell lung cancer in Turkish population. *Balkan Med J*. 2017;34(6):567–71.
82. Hsu LH, Chu NM, Kao SH. Estrogen, estrogen receptor and lung cancer. *Int J Mol Sci*. 2017;18(8):1–17.
83. Zhang Y, Kang S, Fang W, Hong S, Liang W, Yan Y, et al. Impact of

- smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: A meta-analysis. *Clin Lung Cancer*. 2015;16(2):144-151
84. Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, et al. Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications. *Clin Cancer Res*. 2009;15(18):5646–5661.
 85. AlGharras A, Kovacina B, Tian Z, Alexander JW, Semionov A, van Kempen LC, et al. Imaging-Based Surrogate Markers of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma: A Local Perspective. *Can Assoc Radiol J*. 2020;71(2):208–16

